Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.13 USD | -4.68% | +6.42% | +6.42% |
20/05 | Barclays Adjusts Price Target on GoodRx to $10 From $9, Maintains Overweight Rating | MT |
17/05 | UBS Adjusts Price Target on GoodRx Holdings to $9 From $8, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.42% | 280.65Cr | |
+31.62% | 27TCr | |
+5.00% | 14TCr | |
+30.81% | 9.62TCr | |
+7.51% | 9.25TCr | |
+64.02% | 6.01TCr | |
+15.24% | 4.8TCr | |
+25.78% | 3.79TCr | |
+0.15% | 3.57TCr | |
+15.12% | 2.92TCr |
- Stock Market
- Equities
- GDRX Stock
- News GoodRx Holdings, Inc.
- GoodRx Expects Positive Q4 Momentum to Carry Into 2024, RBC Says